Beijing Wehand-Bio Pharmaceutical Co., Ltd.

北京五和博澳药业股份有限公司

Develops and commercializes natural medicine-based therapies and drug delivery systems in China, with one marketed drug for type 2 diabetes and a pipeline targeting PCOS, obesity, and breast cancer.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Distribution model
• Single product, business line or region
• Pricing policy and price changes
• Capacity and utilisation
• Losses and path to profitability
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Non-IFRS measures and adjustments
• Related-party transactions and balances
• Chapter 18A biotech